Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive adjuvant/neoadjuvant pyrotinib in HER2-positive node-positive early breast cancer
ChiCTR2200058746Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- May 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pyrotinib in breast cancer (2 arms), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: invasive disease-free survival. Planned start May 2022; status: not yet recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200058746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058746.